1. Keisner SV, Shah SR. Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma. Drugs. 2011; 71:443–454.
2. Gaertner KM, Caldwell SH, Rahma OE. A case of retinal tear associated with use of sorafenib. Front Oncol. 2014; 4:196.
Article
3. Wegner A, Khoramnia R. Neurosensory retinal detachment due to sunitinib treatment. Eye (Lond). 2011; 25:1517–1518.
Article
4. Fraunfelder FT, Fraunfelder FW. Oral anti-vascular endothelial growth factor drugs and ocular adverse events. J Ocul Pharmacol Ther. 2018; 34:432–435.
Article
5. Hasan R. A retinal tear induced by pazopanib therapy: a case report. Med Forum. 2015; 16:13.
Article
6. Mitry D, Charteris DG, Fleck BW, et al. The epidemiology of rhegmatogenous retinal detachment: geographical variation and clinical associations. Br J Ophthalmol. 2010; 94:678–684.
Article
7. Etminan M, Forooghian F, Brophy JM, et al. Oral fluoroquinolones and the risk of retinal detachment. JAMA. 2012; 307:1414–1419.
Article
8. Ponsioen TL, Hooymans JM, Los LI. Remodelling of the human vitreous and vitreoretinal interface a dynamic process. Prog Retin Eye Res. 2010; 29:580–595.
9. VanderBeek BL. Oral fluoroquinolones, retinal detachments, and claims database studies. JAMA Ophthalmol. 2016; 134:422–423.
Article
10. Sadaka A, Giuliari GP. Proliferative vitreoretinopathy: current and emerging treatments. Clin Ophthalmol. 2012; 6:1325–1333.
11. Georgalas I, Paraskevopoulos T, Koutsandrea C, et al. Ophthalmic metastasis of breast cancer and ocular side effects from breast cancer treatment and management: mini review. Biomed Res Int. 2015; 2015:574086.
Article
12. Novak MA, Welch RB. Complications of acute symptomatic posterior vitreous detachment. Am J Ophthalmol. 1984; 97:308–314.
Article
13. Krohn J, Seland JH. Simultaneous, bilateral rhegmatogenous retinal detachment. Acta Ophthalmologica Scandinavica. 2000; 78:354–358.
Article
14. Kumar R, Knick VB, Rudolph SK, et al. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther. 2007; 6:2012–2021.
Article
15. Csaky KG, Dugel PU, Pierce AJ, et al. Clinical evaluation of pazopanib eye drops versus ranibizumab intravitreal injections in subjects with neovascular age-related macular degeneration. Ophthalmology. 2015; 122:579–588.
Article